3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooley, AJ; Frisbie, DD; Grauer, GF; Longhofer, SL | 1 |
| Cooley, AJ; Culham, CA; Frisbie, DD; Grauer, GF; Johnson, HC; Longhofer, SL; Schultz, KT | 1 |
2 other study(ies) available for 3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid and Bright Disease
| Article | Year |
|---|---|
Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs.
Topics: Animals; Antibodies; Concanavalin A; Creatinine; Dog Diseases; Dogs; Glomerular Filtration Rate; Glomerulonephritis; Immune Complex Diseases; Kidney; Male; Proteinuria; Pyridines; Thromboxane B2; Thromboxane-A Synthase | 1992 |
Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Concanavalin A; Dinoprostone; Disease Models, Animal; Dogs; Glomerular Filtration Rate; Glomerulonephritis; Immune Complex Diseases; Kidney; Kidney Glomerulus; Male; Pyridines; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1991 |